Agree Realty Corporation logo ADC - Agree Realty Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 22
HOLD 9
SELL 0
STRONG
SELL 0
| PRICE TARGET: $83.94 DETAILS
HIGH: $91.00
LOW: $80.00
MEDIAN: $83.50
CONSENSUS: $83.94
UPSIDE: 11.24%

Stock News

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs.

May 21, 2026 01:05 PM • prnewswire.com
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.

May 18, 2026 11:15 PM • newsfilecorp.com
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' due to the early-stage pipeline, competitive landscape, and unproven efficacy/safety of modified ADCs. Key catalysts include phase 1 data readouts for HWK-007 and HWK-016 in 1H 2027 and an IND filing for HWK-206 in mid-2026.

May 15, 2026 12:25 AM • seekingalpha.com
Agree Realty Declares Monthly Common and Preferred Dividends

Agree Realty Declares Monthly Common and Preferred Dividends

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable June 12, 2026 to stockholders of.

May 12, 2026 12:05 PM • businesswire.com
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis.

May 06, 2026 06:25 PM • globenewswire.com
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution.

May 06, 2026 04:00 AM • businesswire.com
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

May 04, 2026 03:30 AM • prnewswire.com
Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different League

Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different League

Agree Realty (ADC) continues to outperform peers, demonstrating resilient growth despite higher interest rates and economic uncertainty. ADC reported robust Q1 results: 8% AFFO and core FFO growth, $424M invested at a 7.1% cap rate, and a 99.7% occupancy rate. With an A-rated balance sheet, low leverage (3.2x pro forma), and strong liquidity, ADC is well-positioned for accelerated growth as rates decline.

May 01, 2026 04:30 AM • seekingalpha.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

May 01, 2026 12:05 AM • prnewswire.com
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.

Apr 29, 2026 12:15 PM • globenewswire.com
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

Apr 27, 2026 03:30 AM • prnewswire.com
Agree Realty: Reliable Dividend Income To Weather The Macro Storm

Agree Realty: Reliable Dividend Income To Weather The Macro Storm

Agree Realty remains a Buy, supported by strong Q1 results, a robust investment pipeline, and prudent management amid macro uncertainty. ADC posted 7.9% AFFO per share growth in Q1, reaffirmed 2026 guidance, and maintains an attractive financial position. The monthly dividend was raised to $0.267 (4.15% yield), with a ~70% payout ratio based on their AFFO guidance, while preferred shares (ADC.PR.A) offer an attractive 6.21% yield.

Apr 24, 2026 10:31 PM • seekingalpha.com

Price Targets